Aims: To evaluate the inhibitory activity of probiotics against oral Candida species. Methods and Results: Four commercial probiotic products were screened. Bacillus subtilis R0179 was found to have a significant antifungal effect. Bacillus subtilis-Candida interactions were evaluated using disc diffusion tests, confocal laser scanning microscopy, scanning electron microscopy and interaction with engineered human oral mucosa tissue. Bacillus subtilis exhibited clear zones of inhibition for Candida albicans and Candida parapsilosis but not for Candida krusei. A remarkable reduction in the number of Candida cells and abundant Candida cell death were visualized with confocal laser scanning microscopy. Shrinkage and deformation of Candida cells was observed using scanning electron microscopy. Culture of C. albicans on engineered human oral mucosa tissues resulted in the presence of a large number of yeast cells on the tissue surface and the development of large-scale tissue damage. However, comparatively fewer Candida cells were observed on B. subtilis-treated tissues. We also use ultra performance liquid chromatography/time of flight mass spectrometry (UPLC/TOF MS) to explore the preliminary antifungal mechanism of B. subtilis R0179 and to detect that whether it can secrete an antifungal agent, Iturin A. Conclusions: Bacillus subtilis R0179 exhibits a significant inhibitory effect on the growth of Candida species. Significance and Impact of the Study: Bacillus subtilis has the potential to be used in the prevention or treatment of oral candidiasis.
Introduction
Probiotics are micro-organisms that have been claimed to provide health benefits when consumed. In the last two decades, many studies have focused on their roles and effects on the maintenance of health (Lee and Kim 2014) . Current researches have shown that the balance between beneficial and pathogenic bacteria is essential in order to maintain health (Bizzini et al. 2012) . Probiotics confer health benefits on the host via diverse mechanisms, including preventing pathogen adherence, producing bacteriocins, changing the pH, producing vitamins and immunological modulation (Hanson et al. 2014) .
Probiotics can be applied to plant diseases, animal diseases and human diseases. Most of the clinical interest in probiotics has been focused on their use in the prevention or treatment of gastrointestinal diseases. Probiotics can reduce the duration of acute diarrhoea and improve inflammatory bowel disease symptomatology (Verna and Lucak 2010) . Probiotics can also be applied to treat conditions affecting the respiratory tract, urinary tract, skin and vagina (Vandenplas et al. 2015) . There is an extremely diverse range of potential biological effects, and new functional activities are constantly being explored. Probiotic bacteria have proven beneficial for a number of health conditions including allergic diseases, metabolic syndrome and infectious diseases (Rijkers et al. 2010) . Some infectious diseases cannot be cured by antibiotics but can be cured by beneficial microbes. For example, the Clostridium difficile infection can be caused by prolonged use of antibiotics, so it is very difficult to treat it using antibiotics (Bakken et al. 2011) . However, it can be cured by beneficial microbes (Van Nood et al. 2013) . Infusion of health donor faeces into the colon can correct the imbalance and enable normal bowel function in patients with the Cl. difficile infection, because faeces from health donors can re-establish the wide diversity of the intestinal flora (Brandt et al. 2012; Saha et al. 2013) .
The human oral cavity, gastrointestinal tract and vagina have a lot in common (Tlaskalova-Hogenova et al. 2004) . They all contact with the outside environment and harbour micro-organisms (Relman and Falkow 2001) . It has been reported that most vaginal bacteria originate from intestinal microbes (Hanson et al. 2014) . Oral bacteria and intestinal bacteria are also linked by saliva (Saha et al. 2012) . The oral cavity can also share flora with the vagina. A study shows that the treatment of the male sexual partner's Candida colonization (oral cavity, penile coronal sulcus, seminal fluid) seems to be important in the prevention of recurrent vulvovaginitis (Spinillo et al. 1992) .
Over the last few years, it has also been suggested that probiotics could be used to maintain oral health. Probiotics have been shown to modulate the oral microbiota, specifically inhibiting the growth of pathogens such as Streptococcus mutans, a cariogenic bacterium and Candida albicans (C. albicans), an organism responsible for the initiation and progression of oral candidiasis (Saha et al. 2013) . Oral candidiasis is a common opportunistic fungal infection caused by Candida species, most commonly C. albicans (Coco et al. 2008) . Candida albicans can also cause intestinal candidiasis and vulvovaginal candidiasis. In the last two decades, C. albicans has been given much more attention due to the increased incidence with the rise in the number of immunocompromised patients following the AIDS epidemic, overuse and misuse of broadspectrum antibiotics and aggressive anticancer therapy (Cutler et al. 2007) . Nowadays due to the rapid development of resistance to common antifungal drugs (Hoehamer et al. 2010) , such as fluconazole (Lopez et al. 2001) , new strategies are urgently needed to prevent and treat infections caused by these pathogens.
A few studies have focused on using probiotics to prevent infections caused by C. albicans in the oral cavity (Ahola et al. 2002; Hatakka et al. 2007; Sutula et al. 2012) . In a previous study, the consumption of cheese that contains the probiotics Lactobacillus GG, Lactobacillus rhamnosus LC705 and Propionibacterium freudenreichii ssp. shermanii JS was shown to be an effective means of controlling oral Candida and hypo-salivation in the elderly (Hatakka et al. 2007) . Additionally, cheese containing Lactobacillus GG and Lact. rhamnosus LC705 reduced the level of salivary yeasts in healthy adults (Ahola et al. 2002) . However, the effectiveness of probiotics for oral candidiasis remains controversial. For example, it was reported that consumption of a probiotic drink containing Lactobacillus casei strain Shirota had no overall effect on selected oral parameters in healthy denture wearers (Sutula et al. 2012) . Researches into the use of probiotics to treat oral candidiasis are very limited and the actual antifungal mechanism of probiotics remains unclear. Therefore, further investigations are required to investigate the effectiveness of using probiotics to treat oral Candida species, and the mechanism by which this occurs.
The aim of our study is to evaluate the in vitro inhibitory activity of four commercial probiotic products against oral Candida species and to investigate the possible anti-Candida mechanisms. The ultimate goal of the study is to indicate potential applications of probiotic products for oral candidiasis.
Materials and methods

Probiotic products and microbial culture
Four probiotic products were cultured on various agar media. Entrocoordinatibiogen (Shenyang NO. 1 Pharm. Co., Ltd., Shenyang, Liaoning, China), which contains Bacillus licheniformis, was propagated on Luria-Bertani (LB) agar (02-137; AOBOX Biotechnology, Beijing, China). Medilac-Vita (Hanmi Pharm. Co., Ltd., Beijing, China), containing Bacillus subtilis and Enterococcus faecium, was propagated on LB agar. Golden Bifidobacterium tablets (Inner Mongolia ShuangQi Pharmaceutical Co., Ltd., Hohhot, Inner Mongolia, China), containing Bifidobacterium, Lactobacillus bulgaricus and Streptococcus thermophiles was propagated on de Man, Rogosa and Sharpe (MRS) agar (02-291; AOBOXing Product). Bifid Triple Viable (Shanghai Pharmaceuticals Holding Co., Ltd., Shanghai, China), containing Bifidobacterium, Lactobacillus acidophilus and Enterococcus faecalis, was propagated on MRS agar.
Candida strains and susceptibility testing
Five C. albicans clinically isolated from oral candidiasis patients were studied as well as four standard strains, C. albicans ATCC 90028, C. albicans SC5314, Candida krusei ATCC 6258 and Candida parapsilosis ATCC 22019. All the Candida strains were propagated on Sabouraud Dextrose Agar (SDA) (02-359; AOBOXing Product) at 37°C. Disc diffusion testing of the four probiotic prod-ucts was performed as described in the Clinical and Laboratory Standards Institute (CLSI) (formerly the National Committee for Clinical Laboratory Standards (NCCLS)) document M44-A, with minor modifications. Specifically, SDA was used instead of Mueller-Hinton agar. The agar surface was inoculated using a swab dipped in a suspension of Candida species adjusted to the turbidity of a 0Á5 McFarland standard, and the plates were dried at room temperature for 15 min before placing the blank discs on the surface. Different probiotics (12Á5 ll of centrifuged deposit per disc, 3 9 10 10 CFU ml À1 ) and fluconazole (Flz, 12Á5 ll per disc, 25 lg as quality control) discs were placed onto the surface of the inoculated plates. The plates were incubated at 37°C for 48 h, at which point the inhibition diameters around the discs were measured. The experiments were performed in triplicate.
Confocal laser scanning microscopy
The suppressive effect of B. subtilis on C. albicans biofilm formation was confirmed by confocal laser scanning microscopy (CLSM) and Live/Dead staining. Biofilms on plastic coverslips stained using the Live/Dead BacLight Bacterial Viability Kit (Molecular Probes, Eugene, OR, USA). Using this assay, cell viability was determined, as live cells were stained fluorescent green; while those with damaged membranes were stained fluorescent red (Rene et al. 2014) . Each plastic coverslip was immersed in 200 ll of the Live/Dead BacLight Bacterial Viability reagent and incubated for 20 min in the dark at 30°C. Afterwards, the stained samples were viewed using a CLSM system equipped with two lasers (488 and 543 nm). We also verified the viable and nonviable yeast cells by visual inspection according to their distinct fluorescent emissions. The experiments were performed three times.
Scanning electron microscopy
Visualization of morphological changes of C. albicans was achieved using scanning electron microscopy (SEM). Samples were fixed and dehydrated as described previously (Chandra et al. 2008) . The stubs were sputtercoated with Au/Pd (60/40) for 60s using a sputter-coating machine. Next, the stubs were transferred to the sampleholding platform in the scanning electron microscope. The specimen surface was scanned and representative areas were selected and recorded.
Interaction of Candida albicans with engineered human oral mucosa
Normal human gingival cells (fibroblasts) and the HaCaT cell line (epithelial cells) were obtained from the central laboratory at the Peking University School of Stomatology. The fibroblasts were cultured in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% fetal bovine serum (FBS). The epithelial cells were cultured in Dulbecco's modified Eagle's (DME's)-Ham's F12, with 10% FBS medium. The engineered human oral mucosa (EHOM) model was set up as described previously (Rouabhia and Deslauriers 2002) . Candida albicans (200 ll; 1 9 10 6 CFU ml À1 ), with or without B. subtilis R0179 (1 9 10 9 CFU ml À1 ), were overlaid on the top of the EHOM and co-cultured at 37°C for 24 h. The samples were fixed and periodic acid-Schiff (PAS) staining was performed.
UPLC/TOF MS
The B. subtilis R0179 strains were activated in LB plates at 37°C for 24 h. The seed cultures were cultivated in 40 ml LB medium by 10% amount of inoculum at 30°C, under 150 rev min À1 for 2 days. The extraction and measurement of Iturin A was carried out as previously reported (Hsieh et al. 2008) . Putative lipopeptide was analysed by means of UPLC/TOF MS, using the following solvent gradient for chromatography (0Á4 ml min À1 , 45°C): starting with a mixture (10/90, v/v) of water and methanol, the methanol content was increased to 100% within 8 min, and then kept constant for 1 min.
Statistical analysis
Statistical analysis was performed using GRAPHPAD PRISM 5 (GraphPad Software, San Diego, CA). The total number of CFU and the percentage of C. albicans death were compared using Student's t-test. P values of <0Á05 were considered to indicate significance.
Results
Anti-Candida activity by disc diffusion testing
Among the four probiotic products, only Medilac-Vita exhibited a clear inhibition zone against C. albicans, while Entrocoordinatibiogen, Golden Bifidobacterium tablets and Bifid Triple Viable did not display inhibition activity in the disc diffusion assay upon screening. Subsequently, we isolated and tested the bacteria components, B. subtilis and Ent. faecium, respectively, from Medilac-Vita. It transpired that B. subtilis exhibited rather strong anti-Candida activity with clear zones of inhibition against C. albicans ATCC 90028 (Fig. 1a) , C. albicans SC5314 (Fig. 1b) and C. parapsilosis ATCC 22019 (Fig. 1d) , although it did not exhibit notable inhibition against C. krusei ATCC 6258 growth (Fig. 1c) . The diameters of the circular zones of C. albicans ATCC 90028 and five clinical C. albicans isolates are summarized in Table 1 . The circular zone of growth inhibition induced by B. subtilis is much clearer than that induced by fluconazole, which indicating that B. subtilis may have direct fungicidal effect compared to fluconazole, which has a low fungicidal potential.
Cell viability determination by CLSM
CLSM revealed a remarkable reduction in Candida cells in the Flz-treated group (P < 0Á001) and the B. subtilistreated group (P < 0Á001), compared to the control group (Figs 2 and 3a) . We also quantified the percentage of dead yeast cells according to their distinct fluorescence emissions by visual counting (Figs 2 and 3b) (Jin et al. 2005) . The percentage of dead Candida cells was significantly increased in the Flz group (P < 0Á001) and the B. subtilis (P < 0Á05) group compared to the blank group. Bacillus subtilis prevented the formation of a biofilm through the inhibition of hyphae formation, which led to a decrease in the yeast cell population.
Morphological change of Candida albicans by SEM
Shrinkage and deformation of C. albicans cells was observed when co-cultured with B. subtilis. This was caused by membrane collapse. As is shown in the SEM images (Fig. 4) , Candida cells in the blank control group were round and plump (Fig. 4a) . However, in the Flz group (Fig. 4d ) and the B. subtilis (Fig. 4b) group, many Candida cells appeared to have shrunk and were deformed.
Bacillus subtilis protects EHOM from damage caused by Candida albicans
Fungal invasion of this tissue was consistent with largescale tissue damage and the epithelial layer was totally separated from the fibroblast layer. In the control group, abundant C. albicans (Fig. 5a ) covered most of the surface of untreated EHOM. However, fewer C. albicans organisms were observed on B. subtilis-treated EHOM (Fig. 5b) , which exhibited more minor tissue damage than was evident in the control group.
Iturin A can be detected in Bacillus subtilis R0179 supernatant by UPLC/MS Peaks in the chromatograms were identified by comparing their migration times with Iturin A standard sample and Iturin A secreted by B. subtilis R0179. Figure 6 shows the peaks of Iturin A in standard and isolated from B. subtilis R0179 supernatant (Fig. 6 ). Iturin A can be detected in B. subtilis R0179 supernatant. The secretion of the antifungal agent Iturin A by B. subtilis R0179 maybe the main antifungal mechanism against Candida species.
Discussion
Candida species are the major cause of oral and oesophageal infections (Webb et al. 1998) . Patients with AIDS, hypo-salivation and diabetes mellitus, as well as those with poor oral hygiene have the greatest risk of developing oropharyngeal candidiasis (Ishijima et al. 2012) . More importantly, Candida species have gained an increased resistance towards common antifungal drugs (Donlan and Costerton 2002) . As a result, new strategies and agents are needed to prevent infections caused by these pathogens. Some probiotic strains, such as Lactobacilli, have been used to treat and prevent vaginal fungal infections and it has been recommended that they be used in recurrent vulvovaginal candidiasis (RVCC) (Hilton et al. 1995) .
However, whether probiotics can be as effective in treating oral candidiasis remains a question. In this study, we aimed to detect the antifungal activity of probiotic products against oral Candida isolates in vitro. We found that B. subtilis might act as a potential candidate for the prevention and treatment of oral candidiasis.
Bacillus species have been used as probiotics for at least 50 years with the Italian product Enterogermina â registered in 1958 as an over-the-counter medication (Mazza 1994; Hong et al. 2005) . Scientific interest in Bacillus species as probiotics, though, has only arisen in the last 15 years. Bacillus species, including B. subtilis are important in the biological control of a number of plant and animal diseases (Chaurasia et al. 2005; Anderson et al. 2013) . A few studies have indicated that B. subtilis might also be potentially applied to treat oral diseases. One study (Tsubura et al. 2009 ) demonstrated that a B. subtilis mouth wash had a positive effect on human patients with periodontitis and it was hypothesized that B. subtilis in mouth wash would adhere to and populate the periodontal tissue in conjunction with other oral bacteria and exhibit beneficial effects. Another study (Tsubura et al. 2012) demonstrated that a tablet (VITALREXTM (VL)) containing B. subtilis DB9011 is an effective oral probiotic material for patients with periodontitis. Our unpublished data show that B. subtilis can be isolated 24 h later after using Medilac-Vita mouthwash, which indicates that the adhesive property of B. subtilis to oral mucosa might be an important part of the probiotic functions. However, the mechanism by which B. subtilis adheres to oral epithelium needs to be further studied. EHOM is well-organized and stratified tissue in which epithelial cells can express proliferating keratins such as Ki-67, K14 and K19, as well as differentiating keratin (K10). EHOM is also able to secrete IL-1b, IL-8, TNF-a, gelatinase-A and gelatinase-B (Rouabhia and Deslauriers 2002) . In this study, an EHOM model has been used to study oral candidiasis, which highly resembles the native oral mucosa. It was revealed that B. subtilis R0179 was found to significantly inhibit the growth of C. albicans in co-culture and with EHOM. Bacillus subtilis treatment of EHOM tissue resulted in fewer Candida cells and less tissue damage compared to controls, which is consistent with the in vitro inhibitory effect. This study was the first time EHOM has been used to study the interaction between C. albicans and B. subtilis. The findings provided initial evidence of the in vitro anti-Candida activity of B. subtilis.
To date the exact mechanism by which B. subtilis inhibits Candida growth is not fully understood. Studies suggest that probiotics might prevent Candida growth through multiple mechanisms (Elahi et al. 2005) . It was reported that B. subtilis has antifungal properties and some strains of B. subtilis can secrete antifungal agents including Iturin A, Surfactin and Fengycin (Tabbene et al. 2011) . In our study, the secretion of Iturin A by B. subtilis R0179 was detected by UPLC/MS. Shrinkage and deformation of Candida cells were observed using SEM. This was caused by the leakage of intracellular plasma. These morphological changes may possibly have been caused by Iturin A, given its ability to pass through the cell wall and disrupt the plasma membrane (Thimon et al. 1995) .
Candida species can be found in the oral cavity, intestinal tract, vagina and skin. Candida may affect other parts of the body. A study shows that infection of vulvovaginal candidiasis is highly associated with the concurrent infection of intestinal Candida (Lin et al. 2011) . Control of oral Candida by probiotics might be beneficial for intestinal and vaginal infection of by C. albicans.
Bacillus subtilis R0179 survives passage through the human gastrointestinal tract by oral consumption and is well tolerated by healthy adults at intakes of from 0Á1 to 10 9 10 9 CFU day À1 . Bacillus spores are able to withstand the antimicrobial properties of the gastrointestinal tract and begin to germinate and colonize the large intestine where they can potentially have beneficial effects (Hanifi et al. 2015) . This provides evidence for the possibility that B. subtilis might colonize in the oral cavity, as the environment in the oral cavity is more moderate than that in intestinal tract. Bacillus subtilis might control Candida species in the oral cavity and the intestinal tract at the same time. More evidence is needed to confirm this hypothesis.
In summary, the current in vitro study demonstrates that B. subtilis R0179, isolated from a probiotic product treating gastrointestinal disorder, exhibited anti-Candida activity, and therefore could be a promising alternative probiotic treatment for oral candidiasis. Further studies are needed to confirm these findings.
